Will Star Health and HDFC ERGO cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Aqneursa is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by CDSCO?

The CDSCO named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; CDSCO review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Indian-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The State Medical Council and the CDSCO Zonal Office verifies the active license; the CDSCO application records both the prescribing physician and the dispensing facility.

Can I receive Aqneursa at home?

The dispensing facility must be Indian-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative drug-only band: USD 14,000 to 18,000 per month. Delivered quote within 24h.Get my quote

Aqneursa access in India: the CDSCO named-patient pathway

How patients in the Republic of India legally obtain Aqneursa (levacetylleucine) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in India access Aqneursa (levacetylleucine) for neurologic manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients weighing 15 kg or more through the CDSCO named-patient pathway, a Central Drugs Standard Control Organisation-administered mechanism that allows an Indian-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in INR.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Aqneursa reaches patients in India

Aqneursa (levacetylleucine, an oral modified amino-acid derivative from IntraBio / Zevra Therapeutics, FDA-approved 24 September 2024 for neurologic manifestations of Niemann-Pick disease type C in adult and paediatric patients weighing 15 kg or more, label resource at accessdata.fda.gov) is not visible on the Central Drugs Standard Control Organization SUGAM approved-product search at cdscoonline.gov.in as of 2026-06-01. Indian families access the medicine under the Permission to Import Small Quantities of New Drug for Personal Use, the statutory Form 12-B Permit applied for via Form 12-A under Rules 36 and 36A of the Drugs and Cosmetics Rules 1945 read with the New Drugs and Clinical Trials Rules 2019, pathway page at cdsco.gov.in/Drugs-for-Personal-Use. The application is filed online through the SUGAM portal at cdscoonline.gov.in/CDSCO/Drugs_Personal. CDSCO public materials describe priority Form 12-B issuance within one to two working days once documentation is complete. Where a hospital is the importer-of-record for an admitted named patient, the parallel Import Licence for Personal Use in CT Form-16 under the Second Schedule and Table-1 of the New Drugs and Clinical Trials Rules 2019 applies, rules text at cdsco.gov.in/Acts-and-rules/New-Drugs. The application requires a registered medical practitioner's prescription with National Medical Commission registration number, drug strength and quantity, the patient's NPC1 or NPC2 genetic confirmation, and a treating physician's case summary.

Where Aqneursa is dispensed in India

Aqneursa is an oral powder reconstituted in liquid and administered three times daily; dispensing routes through paediatric neurology, adult neurology, and clinical genetics services with lysosomal storage disorder experience, baseline scoring (SARA, mFARS, or clinical NPC severity scales), and structured longitudinal assessment. Indian Centres of Excellence under the National Policy for Rare Diseases 2021, identified in the policy document at mohfw.gov.in NPRD 2021, host the most-frequent paediatric and adult NPC case load. Relevant centres include the All India Institute of Medical Sciences New Delhi Centre for Genetics and Inherited Metabolic Disorders, at aiims.edu; Christian Medical College Vellore Clinical Genetics and Paediatric Neurology service, at clin.cmcvellore.ac.in; the Postgraduate Institute of Medical Education and Research Chandigarh Genetic Metabolic Diseases unit; Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow Medical Genetics department; the Centre for DNA Fingerprinting and Diagnostics Hyderabad; the Institute of Postgraduate Medical Education and Research / SSKM Hospital Kolkata; and King Edward Memorial Hospital Mumbai Paediatric Genetics service. Among private tertiary nodes, Apollo Hospitals Chennai, Delhi, and Hyderabad, Kokilaben Dhirubhai Ambani Hospital Mumbai, Fortis Memorial Research Institute Gurugram, and Medanta The Medicity Gurugram routinely handle named-patient lysosomal storage disorder imports.

What Aqneursa costs in India

The US wholesale acquisition cost for Aqneursa is reported in the range of approximately USD 368,000 to USD 432,000 per year at the standard FDA-labelled three-times-daily regimen for adult and paediatric patients at and above 15 kg of body weight, sourced from Zevra Therapeutics investor materials and Drugs@FDA at accessdata.fda.gov. No public local-currency benchmark for Aqneursa in INR is observed on the National Pharmaceutical Pricing Authority ceiling-price database at nppaindia.nic.in as of 2026-06-01, consistent with the drug not being CDSCO-registered; do not estimate. Price snapshot: 2026-06-01. Cost layers stacked on the drug cost include international ambient freight (Aqneursa is a stable oral solid that does not require refrigeration per the FDA label), CDSCO permit and customs processing (nominal relative to drug cost), the dispensing facility's drug-handling fee, and the Reserve Meds concierge fee itemised separately on every firm quote. Goods and Services Tax on life-saving medicines sits at 5 percent. Reconstitution at the point of dose, the three-times-daily schedule, and weight-banded sachet selection are operational planning considerations the dispensing pharmacy handles at family training.

Funding and access barriers for Aqneursa in India

The National Policy for Rare Diseases 2021 lists Niemann-Pick disease under its rare-disease groupings as a lysosomal storage disorder. The central financial-assistance ceiling of INR 50 lakh per patient under the Rashtriya Arogya Nidhi umbrella scheme at mohfw.gov.in RAN applies to designated Centres of Excellence and is structured around one-time or short-course interventions. Indefinite three-times-daily Aqneursa dosing on an open-ended basis does not naturally fit the one-time-treatment ceiling, although NPRD coordinators at the Centres of Excellence have applied the ceiling flexibly for some chronic rare-disease therapies. Ayushman Bharat Pradhan Mantri Jan Arogya Yojana at INR 5 lakh per family per year hospitalisation cover does not extend to outpatient lysosomal storage disorder therapy. Indian private health insurers including Star Health, Niva Bupa, HDFC ERGO Health, Care Health, and ManipalCigna assess unregistered named-patient imports case by case; IRDAI has not issued a uniform rule for this category. The dominant funding pattern is family self-pay, often supplemented by diaspora remittance, crowdfunding through Ketto, Milaap, and ImpactGuru, and the Zevra Therapeutics or IntraBio compassionate-access mechanisms where the manufacturer operates one. Indian patient organisations including the Lysosomal Storage Disorders Support Society (LSDSS) provide structured family support and have engaged with the central rare-disease policy framework.

Recent regulatory and access news for Aqneursa

The CDSCO Notifications feed at cdsco.gov.in/Notifications has not posted a levacetylleucine-specific notification over the last 12 months as of 2026-06-01. The Ministry of Health and Family Welfare continues quarterly Health Minister's Committee updates on the NPRD 2021 Centres of Excellence and disease coverage at mohfw.gov.in; no NPC-specific reclassification altering Aqneursa eligibility has been observed in the most recent published roster. On the manufacturer side, Zevra Therapeutics and IntraBio have continued regional rollout of Aqneursa through 2025 and 2026 disclosures, with EMA review continuing in parallel via the European Medicines Agency human medicines portal at ema.europa.eu. India-specific Aqneursa registration filings have not appeared on the SUGAM approved-product search at cdscoonline.gov.in as of the snapshot date.

Where Reserve Meds fits in Aqneursa cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace CDSCO, and we do not replace your dispensing pharmacy. For Aqneursa specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into India, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Aqneursa case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the CDSCO application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

Aqneursa is the second FDA-approved targeted therapy for NPC neurologic manifestations; named-patient files document the NPC1 or NPC2 genetic confirmation and current clinical assessment. Indian specialty referral concentrates these cases at the major academic medical centres and oncology networks.

Next step

If your Indian physician has prescribed Aqneursa and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Aqneursa case Or message us on WhatsApp